Visual Outcomes Of A Non-Diffractive Edof Iol In Cataract Patients With Dry Early Or Intermediate Stage Amd

Acrysof IQ Vivity is a recently developed EDOF lens that utilizes a nondiffractive technology to extend the depth of focus with significantly lower visual disturbances compared with diffractive designs, however limited data are available on its performance in patients with AMD. This study describes the visual outcomes and post-surgical satisfaction of AcrySof IQ Vivity IOLs in patients with early or intermediate AMD

All surgeries and examinations were performed from March 2024 to February 2025 at a single tertiary Care Referral Center: Azienda Ospedaliero-Universitaria di Ferrara – Arcispedale Sant’Anna, Ferrara, Italy.

Study design: prospective observational study of patients affected by cataract and dry early or intermediate stage AMD in both eyes who underwent bilateral cataract surgery with AcrySof IQ Vivity IOL. Sample size is 24 (48 eyes), this is an interim analysis of 19 patients (38 eyes).

Primary outcome: mBCDVA (monocular best-corrected distance visual acuity)

Secondary outcomes: monocular and binocular VA with and without correction for far, intermediate, and near-distance. Binocular Defocus curve (+1.50D -2.50D). Quantification of disabling Glare by Aston Halometer. Assessment of visual discomfort, function, and patient satisfaction, respectively by McAllinden, Catquest-9SF, and IOLSAT. Outcomes were assessed 3 months postoperatively.

At 3 months postop a significant improvement (p<0.05) was observed in mBCDVA (0.35±0.21 vs 0.01±0.03 logMAR), bUDVA (0.45±0.32 vs 0.00±0.01 logMAR), bUIVA (0.58±0.33 vs 0.11±0.10 logMAR), bUNVA (0.68±0.32 vs 0.31±0.16 logMAR), and each of the other secondary outcomes.

A mean VA ≥ 0.2 logMAR was achieved between -1.50 and +1.00 dioptres of defocus.

Catquest-9SF score significantly improved (19.79±4.15 vs 11.00±3.22, p<0.001).

The mean radial extension of haloes was 0.50±0.08 degrees.

A significant improvement (p<0.05) was achieved on McAllinden score (29.63 ±12.96 vs 3.32 ±5.91) and in the number of patients experiencing or bothered by glare, halo or starbursts (78.9% vs 5.3%), with 94.7% of patients satisfied (mean IOLSAT 2.68±3.29).

The results from our study cohort showed significant improvement in far-, intermediate-, and near-distance visual acuity postoperatively, with low rates of photic disorders and good patient satisfaction and spectacle independence.

In conclusion, the AcrySof IQ Vivity IOLs could be an effective solution for providing patients with early to intermediate AMD an improved spectacle-free vision for far-, intermediate-, and near- distances with tolerable dysphotopsia profile.